FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220653500> ?p ?o ?g. }

• W4220653500 endingPage "09" @default.
• W4220653500 startingPage "P4" @default.
• W4220653500 abstract "Abstract Objectives: Recently-published phase I clinical trials have demonstrated promising efficacy of novel HER2-targeted therapy in advanced breast cancers with a HER2 immunohistochemistry (IHC) score of 1+, or 2+ with a non-amplified in-situ hybridization (ISH). This has raised the possibility for changing the categories for clinical interpretation of HER2 in breast cancers into: 1) HER2-negative (HER2 IHC score of 0+), 2) HER2-low (IHC score of 1+, or 2+ with a non-amplified ISH), and 3) HER2-positive (HER2 IHC score of 3+ and IHC score of 2+ with amplified ISH). Earlier studies on low HER2-expressing breast cancers focused on differences between HER2 2+ with negative ISH and HER2 0/1+. The aims of this study are to investigate the clinical, pathologic and molecular features of HER2-low breast cancers, in comparison to HER2-negative breast cancers. Methods: 281 breast cancers with HER2 IHC were diagnosed between 04/2020 and 12/2020 at our institution, including 164 HER2-negative, 87 HER2-low, and 30 HER2-positve cases. The clinicopathologic information and molecular subtyping (Agendia BluePrint) results of HER2-low breast cancers were retrospectively collected, and compared to those of HER2-negative cases. A p-value of &lt; 0.05 was considered statistically significant. Results: HER2-low breast cancers accounted for 31% (87/281) of breast cancers in our study population. The majority of these HER2-low cases were clinical stage I-II, with 6 cases (6.9%) being stage IV. Most of the HER2-low cancers had a HER2 IHC score of 1+ (87%, 76/87), a ductal phenotype (82%, 71/87), histologic grades of 1 or 2 (94%, 82/87), were ER positive (94%, 81/86), PR positive (86%, 74/86), and had luminal molecular subtypes (96%, 83/87). Four patients received neoadjuvant chemotherapy and none of them achieved pathologic complete response. Compared to HER2-negative cancers, HER2-low breast cancers showed a lower Ki-67 (p&lt;0.05), a higher ER positivity (p&lt;0.05), a higher pathologic stage (p&lt;0.05), and were more likely to be of the luminal molecular subtype (p&lt;0.05). There was no significant difference in age, tumor size, histologic type, histologic grade, presence of lymphovascular invasion, PR status, or pathologic nodal stage (Table 1). Conclusions: HER-2 low breast cancers represent a heterogeneous group, and the majority are lower grade, early-stage, hormonal receptor positive, have a HER2 IHC score of 1+, and have a luminal molecular phenotype. This study provides the baseline clinicopathologic and molecular features of HER2-low breast cancers. Additional studies are needed to further elucidate the biology of HER2-low breast cancers. Table 1. Comparison of clinicopathologic parameters and molecular subtypes between HER2-low and HER2-negative breast cancersHER2-Low (n=87)HER2-Negative (n=164)P valueAge (year)66.6264.380.22Tumor size (mm)21.4919.290.49Histologic typeDuctal711390.57Lobular1524Mixed11Histologic grade143640.156239813519pT Stage142880.0452817362Unknown2735PN stage036760.351613210300Unknown2353ER positivity94.2 % (81/86)82.9% (136/64)0.01PR positivity86% (74/86)76.8% (126/164)0.09Ki-67 (%)12.8118.290.03Molecular subtypeLuminal A571050.003Luminal B2630HER210Basal328 Citation Format: Huina Zhang, Hani Katerji, Bradley M Turner, David G Hicks. Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-05-09." @default.
• W4220653500 created "2022-04-03" @default.
• W4220653500 creator A5010774128 @default.
• W4220653500 creator A5018765384 @default.
• W4220653500 creator A5041206547 @default.
• W4220653500 creator A5075171048 @default.
• W4220653500 date "2022-02-15" @default.
• W4220653500 modified "2023-09-28" @default.
• W4220653500 title "Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience" @default.
• W4220653500 doi "https://doi.org/10.1158/1538-7445.sabcs21-p4-05-09" @default.
• W4220653500 hasPublicationYear "2022" @default.
• W4220653500 type Work @default.
• W4220653500 citedByCount "0" @default.
• W4220653500 crossrefType "journal-article" @default.
• W4220653500 hasAuthorship W4220653500A5010774128 @default.
• W4220653500 hasAuthorship W4220653500A5018765384 @default.
• W4220653500 hasAuthorship W4220653500A5041206547 @default.
• W4220653500 hasAuthorship W4220653500A5075171048 @default.
• W4220653500 hasConcept C121608353 @default.
• W4220653500 hasConcept C126322002 @default.
• W4220653500 hasConcept C142724271 @default.
• W4220653500 hasConcept C143998085 @default.
• W4220653500 hasConcept C146357865 @default.
• W4220653500 hasConcept C151730666 @default.
• W4220653500 hasConcept C160798450 @default.
• W4220653500 hasConcept C199360897 @default.
• W4220653500 hasConcept C204232928 @default.
• W4220653500 hasConcept C2779786085 @default.
• W4220653500 hasConcept C41008148 @default.
• W4220653500 hasConcept C530470458 @default.
• W4220653500 hasConcept C71924100 @default.
• W4220653500 hasConcept C83852419 @default.
• W4220653500 hasConcept C86803240 @default.
• W4220653500 hasConceptScore W4220653500C121608353 @default.
• W4220653500 hasConceptScore W4220653500C126322002 @default.
• W4220653500 hasConceptScore W4220653500C142724271 @default.
• W4220653500 hasConceptScore W4220653500C143998085 @default.
• W4220653500 hasConceptScore W4220653500C146357865 @default.
• W4220653500 hasConceptScore W4220653500C151730666 @default.
• W4220653500 hasConceptScore W4220653500C160798450 @default.
• W4220653500 hasConceptScore W4220653500C199360897 @default.
• W4220653500 hasConceptScore W4220653500C204232928 @default.
• W4220653500 hasConceptScore W4220653500C2779786085 @default.
• W4220653500 hasConceptScore W4220653500C41008148 @default.
• W4220653500 hasConceptScore W4220653500C530470458 @default.
• W4220653500 hasConceptScore W4220653500C71924100 @default.
• W4220653500 hasConceptScore W4220653500C83852419 @default.
• W4220653500 hasConceptScore W4220653500C86803240 @default.
• W4220653500 hasIssue "4_Supplement" @default.
• W4220653500 hasLocation W42206535001 @default.
• W4220653500 hasOpenAccess W4220653500 @default.
• W4220653500 hasPrimaryLocation W42206535001 @default.
• W4220653500 hasRelatedWork W1971465952 @default.
• W4220653500 hasRelatedWork W2054159503 @default.
• W4220653500 hasRelatedWork W2058595915 @default.
• W4220653500 hasRelatedWork W2406547867 @default.
• W4220653500 hasRelatedWork W2896532861 @default.
• W4220653500 hasRelatedWork W2934076975 @default.
• W4220653500 hasRelatedWork W3031174193 @default.
• W4220653500 hasRelatedWork W4309487056 @default.
• W4220653500 hasRelatedWork W4323036952 @default.
• W4220653500 hasRelatedWork W2342209702 @default.
• W4220653500 hasVolume "82" @default.
• W4220653500 isParatext "false" @default.
• W4220653500 isRetracted "false" @default.
• W4220653500 workType "article" @default.